Background
==========

Randomized clinical trials are generally considered the most reliable method for evaluating the effects of health care interventions. However, randomized trials vary in design, and different design characteristics may impact on internal validity (risk of bias), external validity (generalizability) and costs (both economical and logistical). One such design characteristic is a run-in period, which is a planned time period from formal patient enrollment to randomization that enables exclusion of certain patients, for example, if they experience harms (see [Box 1](#bx1-clep-11-169){ref-type="boxed-text"}).[@b1-clep-11-169]

In trials with run-in periods, randomization may take place days or weeks after formal enrollment. During this post-inclusion pre-randomization period, all patients receive the same treatment, for example, a placebo ("placebo run-in"), the experimental drug ("active run-in") or observation only ("no-treatment" or "washout" run-in).[@b1-clep-11-169],[@b2-clep-11-169]

###### Run-in periods in randomized clinical trials

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  • What is a run-in period?
   ◦ A run-in period is a time period after inclusion, but before randomization, used to exclude certain patients. Other pre-randomization periods exist, for example, extended screening periods and washout periods. These different pre-randomization periods may overlap in purpose, design and terminology
  • What types of run-in periods exist and which patients are excluded?
   ◦ During the run-in period, all patients receive the same intervention, for example, active treatment, placebo treatment or no intervention. Patients are excluded due to, for example, noncompliance to treatment or data collection, non-response to treatment or response to placebo
  • What are the reasons for using a run-in period?
   ◦ By excluding certain patients, for example, noncompliers or placebo responders, run-in period may increase a study's power, that is, chance of detecting a potential treatment effect
  • What other terms are used for a run-in period?
   ◦ Similar terms used are lead-in periods, single-blind placebo periods and enrichment periods
  • What potential problem does run-in period cause?
   ◦ The use of a run-in period may affect external validity, by exclusion of patients from the clinical study population, as well as internal validity, by the risk of unblinding or exaggeration of the intention-to-treat effect estimate
  • What is needed to assess the possible impact of a run-in period on trial results?
   ◦ We propose that the study reader would want to study the number of excluded patients, reasons for exclusion and their baseline characteristics. These aspects should, therefore, be reported in the trial publications
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The main rationale for a run-in period in a trial is to adjust the selection of patients for the post-randomization phase of the trial. The principal difference between standard screening by eligibility criteria in a trial and the procedures in a run-in phase is that the latter permits exclusions based on observations of patients' compliance or responses to trial interventions. Thus, for example, an active run-in period enables exclusion of patients who respond poorly to the experimental intervention. A placebo run-in period enables exclusion of patients who respond well to the placebo intervention. Both active and placebo run-in periods enable exclusion of patients who do not comply with trial procedures.[@b1-clep-11-169],[@b3-clep-11-169]

The number of exclusions in run-in periods may be considerable. For example, in a trial of the effect of extended-release opioid for lower back pain, 191 out of 459 enrolled patients (42%) were excluded during the active run-in period.[@b4-clep-11-169] In another trial of the effect of aspirin and β-carotene on cardiovascular disease and cancer, 11,152 out of 33,223 patients (34%) were excluded during the run-in period.[@b5-clep-11-169]

Run-in periods can affect the validity of a study's results. When patients are excluded during a run-in period, for example, due to harms or lack of response, the trial population may increasingly differ from the typical clinical patient population. The balance between benefits and harms of the trial intervention may appear more beneficial than if exclusions had not taken place.

Thus, interpretation of results from a trial with a run-in period is challenging as it involves careful consideration of how pre-randomization exclusions of patients could have affected trial validity. Such considerations presuppose access to relevant information on patient exclusions, typically through adequate reporting of the run-in period in the trial publication.

We, therefore, thought it relevant to study run-in periods in randomized clinical trials. Our objectives were to 1) assess the proportion of trial publications that report a run-in period; 2) characterize such trials and the types of run-in periods and 3) evaluate the completeness of reporting.

Materials and methods
=====================

This was an observational study of a random sample of PubMed-indexed trial publications.

Identification of trial publications
------------------------------------

We identified publications indexed in PubMed as "randomized controlled trial" and published in 2014, and listed them in a random order using [random.org](http://random.org).[@b6-clep-11-169] One reference at a time, one author (DL) screened titles and abstracts (and full text if needed) to check if the publication reported a randomized clinical trial. If so, the same author read the full text of the trial publication and determined whether the trial used a run-in period according to our definition below. We continued the process until 25 trials with a run-in period were identified.

Randomized clinical trials were included if they had a parallel, crossover or split-body design (but excluded if they used cluster randomization). We considered trials to be "clinical" if they assessed the benefits or harms of a health care intervention. We planned to include trial publications written in all languages, using Google Translate as an aid.[@b7-clep-11-169]

We operationally defined a "run-in period" as fulfilling either a main or a secondary criterion. The main criterion was that a trial publication had to 1) use one of the following terms: "run-in", "lead-in", "enrichment", "single-blind placebo" or "baseline", indicating a time period after (explicitly reported) registration of trial patients, but before their randomization and 2) explicitly report possible exclusion of patients during this period due to non-response to experimental intervention, harms, response to control intervention, noncompliance to experimental or control intervention or noncompliance to data collection. The secondary criterion was that a trial publication had to 1) explicitly use the following terms: "run-in", "lead-in" or "enrichment", indicating a time period after (explicitly or implicitly reported) registration of trial patients, but before their randomization and 2) report no indications that investigator-driven patient exclusions due to response to, or compliance with, treatments were disallowed. The distinction between trials qualified as run-in trials according to the main and secondary criteria was used in sensitivity analyses (see Supplementary materials).

If the trial publication referred to previous trial publications (eg, published protocols), we included information from these to determine whether a run-in period was reported or not. Thus, "trial publication" in this study means the index publication identified in our sample and previous journal publications on the same trial cited in the index publication.

Data extraction and processing
------------------------------

From the sample of 25 randomized clinical trials with a run-in period as well as a random selection of 100 trials without a run-in period, one author (DL) extracted descriptive data on publication and trial: language, clinical specialty (medical, surgery, others), trial design (eg, parallel, crossover), number of intervention arms, types of control interventions (eg, active or placebo), treatment class (pharmacological or non-pharmacological), number of patients randomized and industry involvement.

We operationally defined an "industry trial" as a trial in which a commercial company (eg, a drug or a device company) had participated in the trial design, and thus had potentially influenced the decision to use a run-in period. A trial was categorized as an industry trial if a drug or device company was listed as "responsible party" or "sponsor" in [ClinicalTrials.gov](http://ClinicalTrials.gov) (or in other trial registries if the trial publication mentioned these), if industry employees had participated in the design of the trial (according to, eg, the trial report), if industry authors were mentioned as co-authors or if the trial was mentioned as industry funded, but did not describe who had designed the study.

From the trial publications reporting a run-in period, the same author (DL) extracted the following additional data: intervention type during run-in period (eg, active, placebo, no intervention), duration of the run-in period, number of patients enrolled and excluded in the run-in period, reasons for exclusion and characteristics at inclusion (the "baseline characteristics"). Furthermore, we noted the term used for run-in period (eg, "run-in" or "lead-in period") and purposes of the run-in period (eg, selecting patients compliant to treatment).

For the publications describing a trial with a run-in period, one author (DL) evaluated the completeness of reporting. We defined complete reporting of a run-in period as the unambiguous description of 1) the number of patients enrolled to the run-in period and the number of patients excluded during the run-in period (and, consequently, the number of patients randomized after the run-in period); 2) the reasons for exclusion of all patients during the run-in period and 3) the characteristics of excluded patients. For each paper, we also noted specifically which of our three criteria were met or not.

A second author (AP) independently repeated the data extraction, assessment of industry involvement and evaluation of completeness of reporting of run-in period. This was done for all 25 run-in trial publications and for 20 randomly selected trial publications not reporting a run-in period. Disagreements were settled by discussion.

Data analysis
-------------

We tabulated descriptive data as numbers (and percentages) or medians (and interquartile ranges \[IQRs\]). For trials with run-in periods, we summarized trial data, run-in period data and completeness of reporting. We also planned to compare patient characteristics for excluded and randomized patients, and we summarized reasons for using a run-in period and the terminology involved. We used Fisher's exact test or Mann-- Whitney *U* test to compare characteristics of trials with and without run-in phases. The software used for data analysis was Microsoft Excel and the Real Statistics Resource Pack.[@b8-clep-11-169]

We performed sensitivity analyses to study the robustness of our results to our definition of a "run-in period" and to our definition of "industry trials" (see Supplementary materials).

Results
=======

Prevalence of trial publications reporting run-in periods
---------------------------------------------------------

We screened 748 PubMed items and identified 470 randomized clinical trials in order to obtain 25 publications (5%) reporting a run-in period ([Figure 1](#f1-clep-11-169){ref-type="fig"}).[@b9-clep-11-169]--[@b33-clep-11-169]

Characteristics of trial publications reporting run-in periods
--------------------------------------------------------------

The trials with run-in periods were larger than trials without (median number of randomized patients 217 and 90, respectively, *P*=0.01). All the run-in trials were published in English. Six of the eight trials with non-pharmacological interventions studied dietary or lifestyle interventions ([Tables 1](#t1-clep-11-169){ref-type="table"} and [2](#t2-clep-11-169){ref-type="table"}).

Also, 16 of 25 trials with a run-in period (64%) were industry trials. This proportion was much higher than among trials without run-in periods (23 out of 82, 28%, *P*\<0.01, the denominator 82 came from disregarding 18 out of 100 trials with unclear industry status; [Table 1](#t1-clep-11-169){ref-type="table"}). Extrapolating the latter proportion of 28% from the 82 trials in the sample to all 445 trials without a run-in period, these would includê125 industry trials. Thus, among all 470 randomized clinical trials with and without run-in periods, there would be a total of 141 industry trials (the sum of 16 and 125) and conversely 329 non-industry trials. It follows that an estimated proportion of publications reporting a run-in period was 11% among industry trials (16 out of 141) and 3% among non-industry trials (9 out of 329).

In the 13 of 25 run-in period trials reporting relevant data, a median of 16% of enrolled patients were excluded during the run-in period (IQR: 5%-24%). In the 24 of 25 trials reporting relevant data, the median duration of the run-in period was 14 days (IQR: 11--28); for 20 trials, the duration of the run-in period was stated as a fixed number, whereas 4 trials reported varying duration (eg, "7±3 days"). The intervention during the run-in period was, in most cases, no intervention (36%, 9 out of 25) or placebo (28%, 7 out of 25). No trial used the experimental treatment of the randomized phase as the run-in intervention ([Table 3](#t3-clep-11-169){ref-type="table"}).

Common purposes of the run-in period were to ensure symptom stability (7 out of 25, 28%), for example, headache frequency over 1 month, and "baseline data collection" (5 out of 25, 2%). Most of the trials (20 out of 25, 80%) used the term "run-in period" (in some variation), whereas 3 trials (12%) used the term "baseline period" and 3 other trials (12%) used "lead-in period".

Completeness of reporting of run-in periods in trial publications
-----------------------------------------------------------------

Two trials (8%) had complete reporting of run-in periods, because there were no exclusions during the run-in period in both cases. In 23 of the trials (92%), the reporting of run-in periods was incomplete according to our definition.

The main reason for incomplete reporting was that trials did not report the characteristics of excluded patients (22 out of 25 trials, 88%). Reporting for the two other aspects was also incomplete in many trials: 48% and 72% of trials did not report number of excluded patients and exclusion reasons, respectively ([Table 4](#t4-clep-11-169){ref-type="table"}).

Sensitivity analysis
--------------------

Our main results were robust to variations in how we operationally defined "run-in period" and "industry trial" (see Supplementary materials).

Discussion
==========

In a representative sample of randomized clinical trial publications, \~1 in 20 reported a run-in period, though in industry trials, the proportion was higher (1 in 10) than in non-industry trials (1 in 30). Trials with run-in periods were typically large industry trials with a placebo control group. A median of 16% of included patients were excluded during run-in periods of a median of 14 days. The run-in procedures differed in design and purpose, but in approximately nine of ten trial publications, the reporting on the run-in period was too incomplete for a meaningful assessment of its potential impact on the trial result.

Strengths and challenges
------------------------

To our knowledge, this is the first study of the characteristics and reporting of run-in periods in a random sample of randomized trials. It was based on contemporary trial publications indexed in PubMed, publications that a clinician may typically access.

Our sample size of 25 trials was chosen to provide an overview of the typical trials with a run-in period. A considerably larger sample size would have been required for a comprehensive overview of possible subgroup characteristics. Some clinical fields were not covered by our sample. For example, we screened \~30 psychiatry trials, but none of these reported a run-in period, even though run-in periods are often believed to occur frequently in psychiatry trials. A previous review has studied the impact of the placebo run-in period on the efficacy of antidepressants. Sixty-seven of the 141 trials included (48%) used a placebo run-in period.[@b34-clep-11-169] Our sample size would also be too small for the detection of small or modest differences between trials with and without run-in periods. We did, however, detect a clear difference between trials with and without a run-in period with respect to industry status.

Our study addressed reporting in trial publications, and not the frequency of conducted but unreported run-in periods. Twelve of the 25 trials from our study were reported in multiple publications, and in 2 cases, we found examples of unreported run-in periods.

We have not investigated whether run-in periods are reported in more detail in other formats than trial publications, for example, protocols, trial registers, study reports or regulatory agency documents. We chose to focus on trial publications as this is by far the most accessible and accessed format for communicating trial findings.

Other similar studies
---------------------

Two previous reviews have addressed run-in periods in trials of patients with chronic pain.[@b35-clep-11-169],[@b36-clep-11-169] The reviews analyzed randomized clinical trials using "enriched enrollment", a variant of the active run-in-period where patients were randomized if they tolerated and responded to active treatment. The first review described characteristics of the trials and enrichment, including discontinuation rate. In the eight included trials, the average discontinuation rate during the enrichment phase was 35% (compared to our median of 16%).[@b35-clep-11-169] The second review identified many of the same trials as the first one.[@b36-clep-11-169] Our study sample did not include active run-in periods that may cause even more frequent patient exclusions due to harms and lack of response.

In our study, we were not able to obtain the characteristics of the excluded patients during the run-in period for any of the 25 trials. We are not aware of reviews of run-in trials that have compared excluded and randomized patients, but publications on single trials have been published. These indicate that the characteristics of excluded patients and randomized patients may be similar or quite different, depending on the study.[@b37-clep-11-169]--[@b41-clep-11-169] It would be relevant for the clinician to inspect the characteristics closely in order to relate the trial population to their own patients.

We did not investigate the impact of run-in periods on post-randomization attrition rates, partly because attrition was reported poorly. However, in a previous review for depression, trials with run-in periods did not seem to lower the attrition rates.[@b42-clep-11-169]

Reviews of interventions for depression, weight loss and chronic pain trials reported that run-in periods also did not seem not to alter the effect sizes.[@b34-clep-11-169],[@b42-clep-11-169]--[@b45-clep-11-169] These empirical results are somewhat at odds with the theoretical reasoning behind using run-in periods. Possible explanations for the unexpected results could be unusual clinical settings, low run-in exclusion rates and low statistical power in the trials or in the reviews in question. Further adequately powered empirical review studies would be interesting.

Mechanisms and perspectives
---------------------------

Approximately 20,000 new randomized clinical trial publications are listed each year in PubMed, so we estimate that about 1,000 trial publications yearly report a run-in period (see Supplementary materials). The impact of such trials is larger than reflected solely by their number because they tend to be comparatively larger industry trials which inform decisions made by physicians and regulatory authorities more often than smaller non-industry trials.

From the perspective of trial logistics, a run-in period is used to make a trial more statistically efficient, that is, better at detecting a presumed effect of an intervention. Assuming a moderately effective intervention, a trial with a run-in phase will need fewer patients to reach a statistically significant result, if 1) patient attrition is reduced, 2) non-adherence to experimental intervention is reduced, 3) missed appointments and resulting lack of data is reduced and 4) fewer patients participate who respond well to placebo or poorly to the experimental interventions.

Similarly, a run-in phase will fit a trial with the restricted objective to evaluate the effect of an intervention under ideal conditions, that is, an "explanatory" or a "proof-of-concept" trial assessing "efficacy", and not a "pragmatic" trial assessing clinical "effectiveness" under conditions close to the expected standard clinical situation.[@b46-clep-11-169]--[@b48-clep-11-169] Thus, a run-in period will tend to improve the sensitivity of the instrument used to detect a treatment effect in compliant patients under a nonstandard clinical situation.

However, from the perspective of users of information derived from clinical trials -- patients, physicians, authors of systematic reviews and clinical guidelines, and policymakers -- the most relevant information are the estimates of the treatment effect sizes applicable to the clinically relevant patient population. A run-in period resulting in pre-randomization exclusion of patients may, if the exclusions are not clearly reported, generally not facilitate such information.

Some proponents argue that active run-in periods can actually imitate the clinical practice of closely monitoring patients when they start a new therapy,[@b49-clep-11-169] and that the relevant effect estimate is the one deriving from compliant patients experiencing minimal harms. However, this is a problematic comparison for three reasons. First, the typical clinical monitoring of patients starting a new therapy is often fairly informal and will often differ considerably from the stricter monitoring in a clinical trial. Second, most clinicians cannot reliably predict or detect noncompliant patients.[@b1-clep-11-169] Third, the risk of harmful effects or anticipated intention-to-treat effect is relevant for those patients who start on the drug. In other words, if patients are excluded in a trial with a run-in period due to noncompliance, a clinician will have considerable difficulty in identifying and treating the patient group for whom a treatment effect has been shown. The problem with applicability also applies with regards to harms of the intervention. In active or placebo run-in periods, the occurrence of harms may be difficult to interpret when no comparison arm is present, and the exclusion of patients who experience harms may underestimate their clinically relevant occurrence.[@b45-clep-11-169],[@b50-clep-11-169],[@b51-clep-11-169] The more efficient a run-in phase is for excluding a specific category of patients, the less directly clinically applicable the trial result may tend to be.

A run-in period may also impact directly on the internal validity of a trial. Half of the patients in trials with an active or placebo run-in period change study intervention at randomization, either from placebo to experimental or vice versa. This enables them to directly compare experimental and control interventions and increases the risk of bias due to unblinding.[@b52-clep-11-169] In our sample, this problem was relevant in 6 out of 25 trials (24%). Furthermore, selection of highly compliant patients who tolerate treatment well may result in a lower post-randomization attrition rate and lower loss of outcome data. This may inflate the estimated effect of assignment of treatment, the intention-to-treat effect.[@b53-clep-11-169] In 7 of 25 trials (12%) in our sample, patient compliance was one of the purposes of the run-in design.

A run-in period may thus impact on both the external and internal validity of a trial. Furthermore, the run-in period may be considered as an example of "bias by design". Bias is usually understood as synonymous with internal validity, but "bias by design" is a broader concept incorporating aspects of external validity, and refers to design features which increase the chance of detecting an effect at the cost of clinical applicability. Other potential examples of bias by design are selection of an inadequate comparator,[@b54-clep-11-169]--[@b57-clep-11-169] short trial duration,[@b54-clep-11-169],[@b57-clep-11-169],[@b58-clep-11-169] selection of clinically irrelevant outcome measures[@b54-clep-11-169],[@b59-clep-11-169] and narrow inclusion criteria.[@b54-clep-11-169],[@b60-clep-11-169],[@b61-clep-11-169] Bias by design has been suggested as one possible mechanism for why industry trials tend to have more favorable conclusions and outcomes than non-industry trials.[@b62-clep-11-169]

Disagreement may exist as to if and when a run-in period affects external and internal validity. However, the proper assessment of the impact of a run-in period on both internal and external validity of a trial relies substantially on adequate reporting. We document that reporting of run-in periods in trial publications is generally inadequate, in line with similar findings for randomization, blinding and attrition.[@b63-clep-11-169]--[@b66-clep-11-169]

Implications
------------

Ideally, a reader of a trial publication wants to be able to apply a reliable trial result to an identifiable group of patients. Thus, it is important that the exclusion process in a run-in period is transparent and that any excluded patients are described in sufficient detail. At present, this is far from the case in the vast majority of trials.

One suggestion for improvement is to include reporting of run-in periods in the next revision of the CONSORT (Consolidated Standards of Reporting Trials) statement. The present version CONSORT 2010 on the reporting of trial publications does not offer advice on how to report the use of run-in periods.[@b67-clep-11-169],[@b68-clep-11-169] We suggest that trials with a run-in period could report this in an adjusted CONSORT flow diagram (eg, interposed between screening and randomization in the current CONSORT flow diagram) and include information on the number of excluded patients and reasons for exclusions. We also suggest that trial publications report the baseline characteristics of excluded patients (eg, in a table).

The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 statement on reporting trial protocols briefly states that a protocol should report run-in periods when describing intervention dosing schedules and in the participant timeline.[@b69-clep-11-169],[@b70-clep-11-169] One option is to expand that section for the revised version of the statement.

While awaiting reporting guideline updates and improved reporting of run-in periods in trial publications, we suggest that results from trials with run-in periods are always interpreted cautiously with respect to external validity and, in many cases, also with respect to internal validity.

Conclusion
==========

The frequency of randomized clinical trials with run-in periods was, on average, \~5%, but three times as frequent in industry trials as compared to non-industry trials. The run-in procedures differed in design and purpose, but a median of 16% of the included patients were excluded during the run-in periods of a median of 14 days. In approximately nine out of ten trial publications, the reporting on the run-in period was too incomplete for a meaningful assessment of its potential impact on the trial results. We suggest that updates of reporting guidelines for randomized trials address run-in periods. We propose the minimum information needed for complete reporting, and we recommend that results from trials with run-in periods are interpreted cautiously with respect to both internal and external validity.

Data sharing statement
======================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Supplementary materials
=======================

Sensitivity analyses
--------------------

### Methods

To study how sensitive our results were to our definition of a run-in period, we evaluated the consequences of a narrower and a broader definition. In comparison with the original definition, the narrower definition only consisted of the main criterion and not the secondary criterion. The broader definition added the terms "washout" to the main and the secondary criterion and "screening" to the main criterion. It also included trials with unclear reporting of the formal time of enrollment, for example, a trial where patients completed a "2-week run-in period to confirm they met the criteria before enrollment".

To study how sensitive our results were to our definition of "industry trial", we defined a broader definition (but not a narrower definition as we did not consider that meaningful). This definition included trials that reported any support, financial or otherwise, from a commercial company (eg, a company provided the study drug free of charge). To study the impact of trials with unclearly reported industry status, we also performed a sensitivity analysis where half of the unclear trials were categorized as industry trials and the other half as not industry trials. Finally, we also presented industry status for the subgroup of pharmacological trials separately.

We also studied how robust our calculation of the frequency of run-in trials among industry trials and non-industry trials was to variation. We calculated the 95% CI of the proportion of industry trials among our sample of trials without run-in periods. Then, we performed the calculations with these upper and lower bounds.

### Results

Our finding of incomplete reporting of run-in periods, and our estimation of proportion of trials reporting run-in periods, was robust to variations in how we operationally defined "run-in period". Nine out of the original 25 trials complied with a narrower definition of the term and 11 additional trials would have been included had we adopted a broader definition. So, our estimation of proportion of trials with run-in periods varied from 9 out of 470 (2%) to 36 out of 470 (8%). The two trials without participant exclusions (ie, with complete reporting) during the run-in period were not among the nine publications complying with the narrower definition, nor did any of the additional eleven trials complying with the broader definition present any of the three aspects required for complete reporting. Therefore, in all relevant scenarios, reporting of run-in periods remained clearly incomplete.

Our assessment of industry involvement of the design of the trial was also robust to unclear categorization in 18 of 100 trials with no run-in period and to our operational definition of industry trial. In the subgroup of trials with pharmacological interventions, industry trials were even more drastically overrepresented (94% vs 39% in trials with and without run-in periods, respectively; see [Table S1](#SD1-clep-11-169){ref-type="supplementary-material"}).

The proportion of industry trials among trials without a run-in period was 28% (23 out of 82, 95% CI =19%--39%). Performing our calculations with the upper bound would reveal that 8.4% of the industry trials and 3.2% of the non-industry trials used a run-in period (using the lower bound: 16.0% and 2.4%, respectively). Therefore, at the least, run-in trials seemed to occur 2.6 times as often in industry trials as in non-industry trials.

Number of randomized clinical trials in PubMed per year
-------------------------------------------------------

On November 23, 2018, we performed a search in PubMed for randomized clinical trials in the years 2013--2017 using the search string: "(Randomized Controlled Trial\[ptyp\]) AND ("2013/01/01"\[Date - Publication\] : "2017/12/31"\[Date - Publication\])". This yielded 122,408 hits, or an average of 24,482 trial publications per year. A conservative number that excluded, for example, misclassifications and duplicates could then be 20,000. In our study sample, the proportion of publications reporting on trials with a run-in period was \~5%, yielding around 1,000 publications per year.

###### 

Industry status in trials with and without run-in periods[a](#tfn16-clep-11-169){ref-type="table-fn"}

  Type of analysis                            Trials reporting a run-in period (n=25)   Trials not reporting a run-in period (n=100)   *P*-value
  ------------------------------------------- ----------------------------------------- ---------------------------------------------- -----------
  Main analysis                                                                                                                        
   Industry trials                            16 (64%)                                  23 (23%)                                       \<0.01\*
   Not industry trials                        9 (36%)                                   59 (59%)                                       
   Unclear                                    0 (0%)                                    18 (18%)                                       
  Sensitivity analysis, broader definition                                                                                             
   Industry trials                            22 (88%)                                  41 (41%)                                       \<0.01\*
   Not industry trials                        3 (12%)                                   38 (38%)                                       
   Unclear                                    0 (0%)                                    21 (21%)                                       
  Subgroup analysis, pharmacological trials                                                                                            
   Industry trials                            16 (94%)                                  18 (35%)                                       \<0.01\*
   Not industry trials                        1 (6%)                                    28 (55%)                                       
   Unclear                                    0 (0%)                                    5 (10%)                                        

**Notes:**

Absolute numbers are shown, as well as percentages in parentheses and *P*-values from Fisher's two-sided exact test. The *P*-value is followed by an asterisk when *P*\<0.05. For the trials without a run-in period, we extracted data from a random sample of 100 trials out of the total 445 trials. Trials were classified as unclear in the main analysis if no information was available on study designers, funding, sponsorship, support or similar. In a sensitivity analysis, we reclassified half of the trials with unclear industry status as industry trials and the other half as not industry trials. In that analysis, the difference between the two groups remained significant (*P*\<0.01). With the broader definition, trials were classified as industry trials if they received any support, financial or otherwise, from a commercial company.
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###### 

General characteristics of randomized clinical trials with and without run-in periods[a](#tfn1-clep-11-169){ref-type="table-fn"}

  Characteristic                                                             Trials reporting a run-in period (n=25)   Trials not reporting a run-in period (n=100)   *P*-value
  -------------------------------------------------------------------------- ----------------------------------------- ---------------------------------------------- ------------
  Number of randomized patients[b](#tfn2-clep-11-169){ref-type="table-fn"}   217 (133-502)                             90 (46-354)                                    0.01^\*^
  Trial design                                                                                                                                                        
   Parallel                                                                  21 (84%)                                  90 (90%)                                       0.31
   Crossover                                                                 4 (16%)                                   7 (7%)                                         
   Split-body                                                                0 (0%)                                    3 (3%)                                         
  Number of treatment arms                                                   2 (2-3)                                   2 (2-2)                                        0.13
  Control group comparators[c](#tfn3-clep-11-169){ref-type="table-fn"}                                                                                                
   Active                                                                    15 (60%)                                  63 (63%)                                       0.82
   Placebo                                                                   15 (60%)                                  18 (18%)                                       \<0.01^\*^
   Standard therapy                                                          2 (8%)                                    20 (20%)                                       0.24
   No treatment                                                              1 (4%)                                    6 (6%)                                         1.00
  Treatment class[d](#tfn4-clep-11-169){ref-type="table-fn"}                                                                                                          
   Pharmacological                                                           17 (68%)                                  51 (51%)                                       0.18
   Non-pharmacological                                                       8 (32%)                                   49 (49%)                                       
  Clinical specialty                                                                                                                                                  
   Medicine                                                                  19 (76%)                                  44 (44%)                                       0.02^\*^
   Surgery                                                                   3 (12%)                                   28 (28%)                                       
   Other                                                                     3 (12%)                                   28 (28%)                                       
  Language                                                                                                                                                            
   English                                                                   25 (100%)                                 91 (91%)                                       0.67
   Chinese                                                                   0 (0%)                                    6 (6%)                                         
   German                                                                    0 (0%)                                    1 (1%)                                         
   Russian                                                                   0 (0%)                                    2 (2%)                                         
  Industry status                                                                                                                                                     
   Industry trials                                                           16 (64%)                                  23 (23%)                                       \<0.01^\*^
   Not industry trials                                                       9 (36%)                                   59 (59%)                                       
   Unclear[e](#tfn5-clep-11-169){ref-type="table-fn"}                        0 (0%)                                    18 (18%)                                       

**Notes:**

For categorical data, absolute numbers are shown, as well as percentages in parentheses and *P*-values from Fisher's two-sided exact test. For numerical data, medians are shown, as well as interquartile ranges in parentheses and *P*-values from the Mann--Whitney *U* test. The *P*-value is followed by an asterisk when *P*\<0.05. For the trials without a run-in period, we extracted data from a random sample of 100 trials out of the total 445 trials.

The number of randomized patients was reported for 24 (96%) of the trials with a run-in period and 98 (98%) of the trials without a run-in period.

One trial could have more control group comparators.

Non-pharmacological trials include trials having more treatment arms where at least one of them is non-pharmacological.

Trials were classified as unclear if no information was available on study designers, funding, sponsorship, support or similar.

###### 

Characteristics of randomized clinical trials with run-in periods

  Trial                                      Subject: treatment                                                              Industry or not   Study design   Study arms                                                                                                                Number of patients enrolled, excluded in run-in, randomized   Run-in type, duration                       Comments on reporting of run-in period                                                                                                                                                                              Purpose of run-in period
  ------------------------------------------ ------------------------------------------------------------------------------- ----------------- -------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  Angelin et al[@b9-clep-11-169]             Hypercholesterolemia: eprotirome                                                Industry          P              Two drug arms with different doses, one placebo arm                                                                       NR, NR, NR                                                    Dietary lead-in, 4 weeks                    Number of patients excluded, baseline characteristics and exclusion reasons not reported. Possibly, no exclusions during run-in period, but this is unclear                                                         "Lead-in" to diet, washout
  Bleecker et al[@b10-clep-11-169]           Asthma: fluticasone furoate/vilanterol                                          Industry          P              Drug and co-drug vs drug vs placebo                                                                                       730, 120, 610                                                 Inhaled corticosteroid only, 4 weeks        Baseline characteristics and detailed exclusion reasons not reported                                                                                                                                                To ensure symptom stability. Baseline data collection. Minimize placebo response
  Casabé et al[@b11-clep-11-169]             Benign prostatic hyperplasia: tadalafil/finasteride                             Industry          P              Drug and co-drug vs placebo and co-drug                                                                                   NR, NR, 696                                                   Placebo, 4 weeks                            Number of excluded patients, baseline characteristics and exclusion reasons not reported                                                                                                                            NR
  Church et al[@b12-clep-11-169]             COPD: umeclidinium and tiotropium                                               Industry          X              Six drug arms with different doses, one alternative drug arm, one placebo arm                                             163, 0, 163                                                   NR, NR                                      No exclusions of patients during run-in. Reporting on exclusion reasons and baseline characteristics deemed complete                                                                                                NR
  De Boever et al[@b13-clep-11-169]          Asthma: an anti-IL-13 mAb                                                       Industry          P              Drug vs placebo                                                                                                           NR, NR, 198                                                   Inhaled corticosteroid, 4 weeks             Number of excluded patients unclear (flowchart numbers do not add up). Baseline characteristics and detailed exclusion reasons not reported                                                                         Stable symptomatic disease
  Diamond et al[@b14-clep-11-169]            Endometriosis: elagolix                                                         Industry          P              Two drug arms with different doses, one placebo arm                                                                       NR, NR, 155                                                   Placebo, 4 weeks                            Number of patients excluded, baseline characteristics and exclusion reasons not reported. Possibly, no exclusions during run-in period, but this is unclear                                                         Minimize placebo effect
  Dodick et al[@b15-clep-11-169]             Migraine: LY2951742, an mAb to calcitonin gene-related peptide                  Industry          P              Drug vs placebo                                                                                                           367, 149, 218                                                 No treatment, 28--38 days                   Baseline characteristics and exclusion reasons not reported                                                                                                                                                         Inclusion based on symptoms over 28 days. To ensure compliance to data collection
  Fitzpatrick et al[@b16-clep-11-169]        CVD in diabetes: intensive weight loss program                                  Not industry      P              Experimental lifestyle treatment vs standard lifestyle treatment                                                          5,579, 434, 5,145                                             No treatment, 2 weeks                       Baseline characteristics and explicit exclusion reasons not reported. Exclusions during run-in given as percentage not absolute number                                                                              Complete self-monitoring
  Haab et al[@b17-clep-11-169]               Overactive bladder: netupitant, a neurokinin-1 receptor antagonist              Industry          P              Three drug arms with different doses, one placebo arm                                                                     325, 79, 246                                                  Placebo, 2 weeks                            Baseline characteristics and exclusion reasons not reported                                                                                                                                                         Inclusion based on symptoms. Baseline symptoms data collection
  Halmos et al[@b18-clep-11-169]             Irritable bowel syndrome: a diet low in FODMAPs or a typical Australian diet    Not industry      X              Experimental diet vs other control diet                                                                                   45, 1, 44                                                     No treatment, 1 week                        One patient withdrew during baseline/run-in period. Missing baseline characteristics, but period was used for baseline characteristic collection. However, some baseline characteristics might have been reported   Baseline data collection
  Hanhineva et al[@b19-clep-11-169]          Impaired glucose metabolism: diet with whole grain, fatty fish and bilberries   Not industry      P              Two experimental diet arms, one control diet                                                                              NR, NR, 131                                                   No treatment, 4 days                        Number of patients excluded, baseline characteristics and exclusion reasons not reported. Maybe no exclusions during run-in, but unclear                                                                            Baseline data collection
  Hoare et al[@b20-clep-11-169]              Depression in HIV/AIDS: escitalopram                                            Industry          P              Drug vs placebo                                                                                                           NR, NR, 105                                                   Placebo, 7±3 days                           Number of patients excluded, baseline characteristics and exclusion reasons not reported. Maybe no exclusions during run-in, but unclear                                                                            To exclude early placebo responders. To ensure compliance to intervention
  Julius et al[@b21-clep-11-169]             Hypertension: candesartan                                                       Industry          P              Drug vs placebo                                                                                                           NR, NR, 809                                                   No treatment, 3 weeks                       Number of excluded patients, baseline characteristics and separate exclusion reasons not reported                                                                                                                   To ensure stable clinical condition: high blood pressure. Possibly to exclude of patients with adverse events
  Laurent and Boutouyrie[@b22-clep-11-169]   Hypertension: olmesartan                                                        Industry          P              Three drug arms with different doses                                                                                      202, 69, 133                                                  Placebo, 2 weeks                            Baseline characteristics and exclusion reasons not reported                                                                                                                                                         NR
  Maneechotesuwan et al[@b23-clep-11-169]    Asthma: generic SFC                                                             Not industry      X              Drug vs other drug                                                                                                        NR, NR, 51                                                    Rescue medication only, 2 weeks             Number of patients excluded, baseline characteristics and exclusion reasons not reported. Maybe no exclusions during run-in, but unclear                                                                            Washout of previous medication
  Marrero et al[@b24-clep-11-169]            Type 2 diabetes: lifestyle intervention, metformin (and troglitazone)           Not industry      P              Drug plus standard treatment vs placebo plus standard treatment vs lifestyle (vs other drug, this arm was discontinued)   4,719, 900, 3,819                                             Placebo, 3 weeks                            Baseline characteristics and separate exclusion reasons not reported                                                                                                                                                To ensure compliance to intervention. To ensure compliance to data collection
  Martinez et al[@b25-clep-11-169]           COPD: Internet-mediated walking program                                         Not industry      P              Active non-drug treatment vs waitlist control                                                                             307, 68, 239                                                  No treatment, 1 week                        Baseline characteristics not reported                                                                                                                                                                               Baseline data collection. To ensure compliance to data collection
  Mugie et al[@b26-clep-11-169]              Functional constipation in children: prucalopride                               Industry          P              Drug vs placebo                                                                                                           NR, NR, 215                                                   Laxative or similar if needed, 1--2 weeks   Number of excluded patients, baseline characteristics and separate exclusion reasons not reported                                                                                                                   Documentation of symptoms. Washout
  Oluleye et al[@b27-clep-11-169]            Heart failure: irbesartan                                                       Industry          P              Drug vs placebo                                                                                                           NR, NR, 4,128                                                 Placebo, 1--2 weeks                         Number of patients excluded, baseline characteristics and separate exclusion reasons not reported. Maybe no exclusions during run-in, but unclear                                                                   Stable clinical condition
  Poulsen et al[@b28-clep-11-169]            Nutrition: new Nordic diet                                                      Not industry      P              Experimental diet vs control diet                                                                                         190, 9, 181                                                   Active control treatment, 1 week            Baseline characteristics not reported                                                                                                                                                                               Standardization to same diet
  Reznik et al[@b29-clep-11-169]             Type 2 diabetes: insulin pump treatment                                         Industry          P              Same drug in two different administration forms                                                                           495, 164, 331                                                 Active control treatment, 2 months          Baseline characteristics not reported                                                                                                                                                                               Achieve optimum injection treatment. To ensure compliance to data collection
  Saneei et al[@b30-clep-11-169]             Childhood metabolic syndrome: DASH diet                                         Not industry      X              Experimental diet vs standard diet                                                                                        60, 0, 60                                                     No treatment, 2 weeks                       Seemingly no exclusions                                                                                                                                                                                             Baseline data collection. Learning data collection
  Siproudhis et al[@b31-clep-11-169]         Fecal incontinence: NRL001                                                      Industry          P              Three drug arms with different doses, one placebo arm                                                                     NR, NR, 466                                                   No treatment, 2 weeks                       Design paper. No data reported even though study enrollment is finished                                                                                                                                             NR
  van Gool et al[@b32-clep-11-169]           Urinary incontinence: bladder training, oxybutynin                              Not industry      P              Drug vs other treatment vs placebo                                                                                        NR, NR, 97                                                    No treatment, 3 months                      Number of patients excluded, baseline characteristics and exclusion reasons not reported. Maybe no exclusions during run-in, but unclear                                                                            To ensure symptom stability: not regained continence
  Zhu et al[@b33-clep-11-169]                Hypertension: telmisartan/amlodipine                                            Industry          P              Drug and co-drug vs co-drug                                                                                               381, 57, 324                                                  Active control treatment, 6 weeks           Explicit baseline characteristics not reported. States that full analysis set was similar to treated set and to run-in set of patients, but data not shown                                                          To exclude responders to A5 monotherapy lowering the blood pressure. To ensure compliance to intervention

**Abbreviations:** CVD, cardiovascular disease; mAb, monoclonal antibody; NR, not reported; P, parallel; SFC, salmeterol/fluticasone combination; X, crossover.

###### 

Characteristics of the run-in period in the 25 trials reporting such a period

  Characteristic                                                                   Measure[a](#tfn7-clep-11-169){ref-type="table-fn"}
  -------------------------------------------------------------------------------- ----------------------------------------------------
  Patient flow[b](#tfn8-clep-11-169){ref-type="table-fn"}                          
   Number of patients enrolled to run-in period                                    325 (190-495)
   Number of patients excluded during run-in period                                69 (9--149)
   Percentage of patients excluded during run-in period                            16% (5%--24%)
  Duration of run-in period in days[c](#tfn9-clep-11-169){ref-type="table-fn"}     14 (11--28)
  Intervention during the run-in period                                            
   Control (placebo)                                                               7 (28%)
   Control (active)                                                                3 (12%)
   Experimental intervention                                                       0 (0%)
   Other intervention[d](#tfn10-clep-11-169){ref-type="table-fn"}                  5 (20%)
   No intervention                                                                 9 (36%)
   Unclear^e^                                                                      1 (4%)
  Main purposes of the run-in period[f](#tfn11-clep-11-169){ref-type="table-fn"}   
   Extended screening, symptom stability                                           7 (28%)
   Baseline data collection                                                        5 (20%)
   Compliance to data collection                                                   3 (12%)
   Exclusion of responders to non-active treatment                                 2 (8%)
   Unclear                                                                         8 (32%)

**Notes:**

For categorical data, absolute numbers are shown, as well as percentages in parentheses. For numerical data, medians are shown, as well as interquartile ranges in parentheses.

Patient flow numbers were reported for 13 out of 25 trials (52%).

Run-in period duration was reported for 24 out of 25 trials (96%).

For example, inhaled corticosteroid in an asthma trial where this treatment was not an intervention arm during the randomized phase.

Some trials reported more than one rationale of the run-in period. Here, we present the purpose most prominently mentioned. For example, four additional trials had compliance to data collection or compliance to run-in intervention noted as a secondary purpose.

###### 

Completeness of reporting on the run-in periods[a](#tfn12-clep-11-169){ref-type="table-fn"}

  Characteristic                                                      Number (percentage)
  ------------------------------------------------------------------- ---------------------
  Overall level of reporting                                          
   Complete reporting[b](#tfn13-clep-11-169){ref-type="table-fn"}     2 (8%)
   Incomplete reporting[c](#tfn14-clep-11-169){ref-type="table-fn"}   23 (92%)
  Reports number of patients excluded during run-in period            
   Yes                                                                13 (52%)
   No                                                                 12 (48%)
  Reports reasons for exclusion of patients                           
   Yes                                                                7 (28%)
   No                                                                 18 (72%)
  Reports baseline characteristics for excluded patients              
   Yes                                                                2 (8%)
   No                                                                 22 (88%)
   Unclear[d](#tfn15-clep-11-169){ref-type="table-fn"}                1 (4%)

**Notes:**

Absolute numbers are shown, as well as percentages in parentheses. A trial run-in period was completely reported if the publication clearly described 1) the number of excluded patients, 2) reasons for exclusion and 3) baseline characteristics of the excluded patients.

Two publications reported trials with run-in periods, but stated to have no exclusions during this phase. They were, therefore, deemed to be completely reported on all three criteria.

One publication was a rationale and design paper reporting on a trial where patient recruitment and randomization was completed. The publication did not present information on the trial's 2-week run-in period. We deemed reporting to be incomplete for all three criteria.

Data were not presented, but excluded and randomized patients were stated to be similar.
